The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review.

摘要: Levomilnacipran, the more active enantiomer of serotonin and norepinephrine reuptake inhibitor (SNRI) milnacipran, was recently approved in US for treatment major depressive disorder (MDD). The drug developed as an extended release (ER) capsule formulation to allow once-daily administration, thereby improving patient adherence. This agent differs from other available SNRIs having a greater potency inhibition relative reuptake. efficacy levomilnacipran ER has been evaluated seven randomised, double-blind clinical trials (one Phase II four III trials, two long-term studies). These studies documented that is generally effective than placebo MDD short-term, whereas no firm evidence exists on relapse prevention. Preliminary suggests may be not only symptoms but also related functioning (social life, work, family life). Short-and longer-term found rate withdrawal therapy due adverse events rather low. Moreover appeared well tolerated. most common effects included nausea, hyperhidrosis, constipation, tachycardia, palpitations, erectile dysfunction ejaculation disorder. As hypertension or orthostatic hypotension occur few patients, cardiovascular safety needs extensively investigated especially treatment. Additional comparator evaluating efficacy, tolerability cost-effectiveness are required better define role relation currently antidepressants including SNRIs.